• COVID-19: Endemic Disease
  • Products
    • ASSURE-100 Home Tests
    • ASSURE-100 POC Tests
    • Buy ASSURE-100 Tests
  • News & Updates
  • Contact Us
Buy Tests
  • COVID-19: Endemic Disease
  • Products
    • ASSURE-100 Home Tests
    • ASSURE-100 POC Tests
    • Buy ASSURE-100 Tests
  • News & Updates
  • Contact Us
  • BUY TESTS
Why Rapid COVID-19 Home Tests Belong in Your Medicine Cabinet

Why Rapid COVID-19 Home Tests Belong in Your Medicine Cabinet

by Oceanit | Jan 22, 2025 | Education, General

Why Rapid COVID-19 Home Tests Belong in Your Medicine Cabinet The COVID-19 pandemic has revolutionized how we think about public health and personal preparedness. One of the most impactful tools to emerge during this time is the rapid home COVID-19 test. Accessible,...
PRESS RELEASE | Oceanit’s ASSURE-100 Rapid COVID-19 Home Test Receives FDA Over-The-Counter Authorization

PRESS RELEASE | Oceanit’s ASSURE-100 Rapid COVID-19 Home Test Receives FDA Over-The-Counter Authorization

by Oceanit | Dec 22, 2022 | International News, National News

PRESS RELEASE | Oceanit’s ASSURE-100 Rapid COVID-19 Home Test Receives FDA Over-The-Counter Authorization FOR IMMEDIATE RELEASE | December 22, 2022 ASSURE-100’s over-the-counter (OTC) authorization permits at-home testing for anyone, with or without symptoms. FDA...

Recent Posts

  • New 2025 COVID Vaccine Rules: What They Mean for Americans
  • Summer 2025 COVID Trends: What to Know & How to Stay Safe
  • CDC Updates 2025 COVID-19 Testing, Isolation & Recovery
  • WHO Pandemic Treaty Aims to Prevent Future Health Crises
  • Should You Keep Rapid Tests for Spring & Summer 2025?

Recent Comments

No comments to show.
Copyright 2025 Oceanit Foundry LLC. The ASSURE-100 Rapid COVID-19 Test has not been FDA cleared or approved, but has been authorized by FDA under an EUA. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
[dsm_icon_list list_alignment=”flex-end” _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” list_alignment_last_edited=”on|phone” list_alignment_phone=”center” sticky_enabled=”0″ list_alignment_tablet=”flex-end”][dsm_icon_list_child text=”Privacy Policy” use_icon=”off” url=”/privacy-policy/” _builder_version=”4.27.4″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_text_color=”#e8e8e8″ text_font_size=”12px” text_text_color_last_edited=”off|desktop” global_colors_info=”{}” text_text_color__hover_enabled=”on|desktop” text_text_color__hover=”#1e73be”][/dsm_icon_list_child][/dsm_icon_list]